Abstract:Abstract Background The gut-liver axis plays a pivotal role in the pathogenesis of hepatocellular carcinoma (HCC). However, the correlations between the gut microbiome and the liver tumor transcriptome in patients with HCC and the impact of the gut microbiota on clinical outcome are less well-understood. Methods Fecal samples collected from HBV-related HCC patients ( n = 113) and healthy volunteers ( n = 100) were subjected to 16S rRNA sequencing of the microbiome. After a rigorous selection process, 32 paired tumor and adjacent non-tumor liver tissues from the HCC group were subjected to next-generation sequencing (NGS) RNA-seq. The datasets were analyzed individually and integrated with clinical characteristics for combined analysis using bioinformatics approaches. We further verified the potential of the gut microbiota to predict clinical outcome by a random forest model and a support vector machine model. Results We found that Bacteroides , Lachnospiracea incertae sedis , and Clostridium XIVa were enriched in HCC patients with a high tumor burden. By integrating the microbiome and transcriptome, we identified 31 robust associations between the above three genera and well-characterized genes, indicating possible mechanistic relationships in tumor immune microenvironment. Clinical characteristics and database analysis suggested that serum bile acids may be important communication mediators between these three genera and the host transcriptome. Finally, among these three genera, six important microbial markers associated with tumor immune microenvironment or bile acid metabolism showed the potential to predict clinical outcome (AUC = 81%). Conclusions This study revealed that changes in tumor immune microenvironment caused by the gut microbiota via serum bile acids may be important factors associated with tumor burden and adverse clinical outcome. Gut microbes can be used as biomarkers of clinical features and outcomes, and the microbe-associated transcripts of host tumors can partly explain how gut microbiota promotes HCC pathogenesis.

The Cutting Edge of Research Advance on the relationship between intestinal microecology and hepatocellular carcinoma

Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory

Modulation of Gut Microbiota by Probiotics to Improve the Efficacy of Immunotherapy in Hepatocellular Carcinoma

Gut Microbial Dysbiosis Associates Hepatocellular Carcinoma Via the Gut-Liver Axis

Research Progress of Gut Microbiota in Hepatocellular Carcinoma

Integrated microbiome and metabolome analysis reveals the interaction between intestinal flora and serum metabolites as potential biomarkers in hepatocellular carcinoma patients

Unveiling the complex relationship between gut microbiota and liver cancer: opportunities for novel therapeutic interventions

Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management

Molecular Immune Mechanism of Intestinal Microbiota and Their Metabolites in the Occurrence and Development of Liver Cancer

Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma

Intratumoral microbiota: an emerging force in diagnosing and treating hepatocellular carcinoma

Systematic Characterization of the Disruption of Intestine during Liver Tumor Progression in the <i>xmrk</i> Oncogene Transgenic Zebrafish Model

Role of Gut Microbiota in Hepatocarcinogenesis

Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances

The Gut Microbiome and Hepatocellular Carcinoma: Implications for Early Diagnostic Biomarkers and Novel Therapies

Systematic Characterization of the Disruption of Intestine during Liver Tumor Progression in the xmrk Oncogene Transgenic Zebrafish Model

Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment

Association between gut microbiota and hepatocellular carcinoma from 2011 to 2022: Bibliometric analysis and global trends

Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation

Understanding gut dysbiosis for hepatocellular carcinoma diagnosis and treatment

Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment